This is a routine corporate governance adjustment with no operational or strategic implications. Traders should not expect stock movement based on this filing.
SLDB drugs
SLDB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $8.39entry
- T+1 · 7mo ago −1.91%α −3.12% · $8.23
- T+5 · 7mo ago +1.19%α −2.10% · $8.49
- T+20 · 6mo ago −8.46%α −16.19% · $7.68
- T+60 · 4mo ago +31.11%α +22.19% · $11.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned from Class III and was immediately reappointed to Class I to balance board composition. The move is procedural and does not reflect a change in leadership or strategy.
Key Facts
- Ilan Ganot resigned from Class III of the Board and was reappointed to Class I effective April 10, 2026
- The change was made to achieve equal balance among the three board classes
- No changes to Ganot's compensation or role responsibilities were made
- Stockholders will be asked to ratify the appointment on an advisory basis at the 2026 Annual Meeting
Financial Impact
No financial impact
Risk Factors
- Advisory ratification at the 2026 Annual Meeting could face shareholder opposition, though unlikely given the procedural nature
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151259 |
| Document: 0001193125-26-151259-index-headers.html | 0001193125-26-151259 |
| Document: 0001193125-26-151259-index.html | 0001193125-26-151259 |
| Document: 0001193125-26-151259.txt | 0001193125-26-151259 |
Track record
14 reports on SLDB
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
- Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
- May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
- May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
- Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
- Apr 10, 202631w ago 8-K Neutral 2/10 Viewing Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
- Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers